Xiaozhi Zhao

Dr. Xiaozhi Zhao


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Theranostics
Verified
Journal Article
Open access
WCWei Chen
Wei Chen
HYHui Yuan
Hui Yuan
WCWenmin Cao
Wenmin Cao
TWTianwei Wang
Tianwei Wang
HYHang Yu
Hang Yu
XZXiaozhi Zhao
Xiaozhi Zhao
Rationale: Renal fibrosis is the terminal manifestation of chronic and irreversible renal disease. Effective therapies other than dialysis are extremely limited. In this study, we investigated the potential effects of targeting elevated interleukin-6 (IL-6) levels in the treatment of renal fibrosis.

20 December 2021 in Nano Letters
Verified
Journal Article
Closed access
HCHuanhuan Chen
Huanhuan Chen
YGYunfei Guo
Yunfei Guo
ZZZhewei Zhang
Zhewei Zhang
WMWenxuan Mao
Wenxuan Mao
CSChenying Shen
Chenying Shen
JWJinhui Wu
Jinhui Wu

1 October 2019 in Biomaterials
Verified
Journal Article
Closed access
HYHang Yu
Hang Yu
TLTingsheng Lin
Tingsheng Lin
WCWei Chen
Wei Chen
WCWenmin Cao
Wenmin Cao
CZChengwei Zhang
Chengwei Zhang
XZXiaozhi Zhao
Xiaozhi Zhao

1 August 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JYJun Yang
Jun Yang
LRLeonardo V. Riella
Leonardo V. Riella
SCSusanne Chock
Susanne Chock
TLTao Liu
Tao Liu
XZXiaozhi Zhao
Xiaozhi Zhao
MSMohamed H. Sayegh
Mohamed H. Sayegh
The programmed death ligand 1 (PDL1)/programmed death 1 (PD1) costimulatory pathway plays an important role in the inhibition of alloimmune responses as well as in the induction and maintenance of peripheral tolerance. It has been demonstrated recently that PDL1 also can bind B7.1 to inhibit T cell responses in vitro. Using the bm12 into B6 heart transplant model, we investigated the functional significance of this interaction in alloimmune responses in vivo. PD1 blockade unlike PDL1 blockade failed to accelerate bm12 allograft rejection, suggesting a role for an additional binding partner for PDL1 other than PD1 in transplant rejection. PDL1 blockade was able to accelerate allograft rejection in B7.2-deficient recipients but not B7.1-deficient recipients, indicating that PDL1 interaction with B7.1 was important in inhibiting rejection. Administration of the novel 2H11 anti-PDL1 mAb, which only blocks the PDL1–B7.1 interaction, aggravated chronic injury of bm12 allografts in B6 recipients. Aggravated chronic injury was associated with an increased frequency of alloreactive IFN-γ–, IL-4–, and IL-6–producing splenocytes and a decreased percentage of regulatory T cells in the recipients. Using an in vitro cell culture assay, blockade of the interaction of PDL1 on dendritic cells with B7.1 on T cells increased IFN-γ production from alloreactive CD4+ T cells, whereas blockade of dendritic cell B7.1 interaction with T cell PDL1 did not. These data indicate that PDL1 interaction with B7.1 plays an important role in the inhibition of alloimmune responses in vivo and suggests a dominant direction for PDL1 and B7.1 interaction.

24 February 2022 in Molecular Cell
Verified
Journal Article
Closed access
XGXin Ge
Xin Ge
MLMengdie Li
Mengdie Li
JYJianxing Yin
Jianxing Yin
ZSZhumei Shi
Zhumei Shi
YFYao Fu
Yao Fu
XQXu Qian
Xu Qian

5 November 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LMLongxiyu Meng
Longxiyu Meng
JFJiayuan Feng
Jiayuan Feng
JGJie Gao
Jie Gao
YZYihong Zhang
Yihong Zhang
WMWenjing Mo
Wenjing Mo
HGHongqian Guo
Hongqian Guo